Insider Transactions in Q4 2025 at Roivant Sciences Ltd. (ROIV)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2025
|
Mayukh Sukhatme President & CIO |
SELL
Other acquisition or disposition
|
Direct |
1,430,882
-7.06%
|
$30,048,522
$21.71 P/Share
|
|
Dec 31
2025
|
Mayukh Sukhatme President & CIO |
SELL
Open market or private sale
|
Direct |
1,018,995
-4.79%
|
$21,398,895
$21.71 P/Share
|
|
Dec 31
2025
|
Mayukh Sukhatme President & CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,449,877
+10.32%
|
$29,398,524
$12.68 P/Share
|
|
Dec 29
2025
|
Mayukh Sukhatme President & CIO |
SELL
Other acquisition or disposition
|
Direct |
436,485
-2.26%
|
$9,166,185
$21.74 P/Share
|
|
Dec 29
2025
|
Mayukh Sukhatme President & CIO |
SELL
Open market or private sale
|
Direct |
311,873
-1.59%
|
$6,549,333
$21.74 P/Share
|
|
Dec 29
2025
|
Mayukh Sukhatme President & CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
748,358
+3.68%
|
$8,980,296
$12.68 P/Share
|
|
Dec 24
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
75,000
-4.34%
|
$1,650,000
$22.53 P/Share
|
|
Dec 24
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
117,848
+6.38%
|
$353,544
$3.85 P/Share
|
|
Dec 24
2025
|
Frank Torti President and Vant Chair |
SELL
Bona fide gift
|
Direct |
110,489
-0.8%
|
-
|
|
Dec 24
2025
|
Frank Torti President and Vant Chair |
SELL
Other acquisition or disposition
|
Direct |
64,891
-0.47%
|
$1,427,602
$22.47 P/Share
|
|
Dec 23
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
200,000
-11.04%
|
$4,400,000
$22.45 P/Share
|
|
Dec 23
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
313,841
+14.76%
|
$941,523
$3.85 P/Share
|
|
Dec 23
2025
|
Richard Pulik CFO |
SELL
Open market or private sale
|
Direct |
406,731
-39.12%
|
$8,948,082
$22.42 P/Share
|
|
Dec 23
2025
|
Richard Pulik CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
260,000
+28.69%
|
$780,000
$3.85 P/Share
|
|
Dec 23
2025
|
Frank Torti President and Vant Chair |
BUY
Grant, award, or other acquisition
|
Direct |
175,380
+1.25%
|
$3,858,360
$22.45 P/Share
|
|
Dec 20
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,129
-0.55%
|
$46,838
$22.41 P/Share
|
|
Dec 17
2025
|
Mayukh Sukhatme President & CIO |
SELL
Other acquisition or disposition
|
Direct |
32,682
-0.17%
|
$751,686
$23.09 P/Share
|
|
Dec 17
2025
|
Mayukh Sukhatme President & CIO |
SELL
Open market or private sale
|
Direct |
26,831
-0.14%
|
$617,113
$23.09 P/Share
|
|
Dec 17
2025
|
Mayukh Sukhatme President & CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
59,513
+0.31%
|
$714,156
$12.68 P/Share
|
|
Dec 17
2025
|
Keith S Manchester |
SELL
Open market or private sale
|
Indirect |
777,332
-1.53%
|
$17,878,636
$23.08 P/Share
|
|
Dec 17
2025
|
Daniel Allen Gold |
SELL
Open market or private sale
|
Indirect |
777,332
-1.53%
|
$17,878,636
$23.08 P/Share
|
|
Dec 17
2025
|
Qvt Financial LP |
SELL
Open market or private sale
|
Indirect |
777,332
-1.53%
|
$17,878,636
$23.08 P/Share
|
|
Dec 16
2025
|
Keith S Manchester |
SELL
Open market or private sale
|
Indirect |
917,282
-2.57%
|
$21,097,486
$23.01 P/Share
|
|
Dec 16
2025
|
Daniel Allen Gold |
SELL
Open market or private sale
|
Indirect |
917,282
-2.57%
|
$21,097,486
$23.01 P/Share
|
|
Dec 16
2025
|
Qvt Financial LP |
SELL
Open market or private sale
|
Indirect |
917,282
-2.57%
|
$21,097,486
$23.01 P/Share
|
|
Dec 15
2025
|
Matthew Gline CEO |
SELL
Other acquisition or disposition
|
Direct |
2,130,659
-3.86%
|
$44,743,839
$21.68 P/Share
|
|
Dec 15
2025
|
Matthew Gline CEO |
SELL
Open market or private sale
|
Direct |
1,740,000
-3.06%
|
$36,540,000
$21.68 P/Share
|
|
Dec 15
2025
|
Matthew Gline CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,870,659
+6.18%
|
$34,835,931
$9.81 P/Share
|
|
Dec 15
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
478,708
-1.4%
|
$10,531,576
$22.05 P/Share
|
|
Dec 15
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
353,745
-1.03%
|
$7,782,390
$22.05 P/Share
|
|
Dec 15
2025
|
Vivek Ramaswamy > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Direct |
832,453
+2.36%
|
$9,989,436
$12.68 P/Share
|
|
Dec 12
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,696,866
-7.42%
|
$56,634,186
$21.96 P/Share
|
|
Dec 12
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,975,858
-5.16%
|
$41,493,018
$21.96 P/Share
|
|
Dec 12
2025
|
Vivek Ramaswamy > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Direct |
4,672,724
+10.87%
|
$56,072,688
$12.68 P/Share
|
|
Dec 11
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,095,550
-3.15%
|
$23,006,550
$21.64 P/Share
|
|
Dec 11
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
774,142
-2.18%
|
$16,256,982
$21.64 P/Share
|
|
Dec 11
2025
|
Vivek Ramaswamy > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Direct |
1,869,691
+5.0%
|
$22,436,292
$12.68 P/Share
|
|
Dec 09
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
200,000
-11.78%
|
$4,000,000
$20.85 P/Share
|
|
Dec 09
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
200,000
+10.54%
|
$600,000
$3.85 P/Share
|
|
Nov 20
2025
|
Eric Venker President & Immunovant CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,051
-0.47%
|
$141,020
$20.27 P/Share
|
|
Nov 20
2025
|
Richard Pulik CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,235
-0.32%
|
$24,700
$20.27 P/Share
|
|
Nov 19
2025
|
Keith S Manchester |
SELL
Open market or private sale
|
Indirect |
1,300,000
-1.71%
|
$26,000,000
$20.21 P/Share
|
|
Nov 19
2025
|
Daniel Allen Gold |
SELL
Open market or private sale
|
Indirect |
1,300,000
-1.71%
|
$26,000,000
$20.21 P/Share
|
|
Nov 19
2025
|
Qvt Financial LP |
SELL
Open market or private sale
|
Indirect |
1,300,000
-1.71%
|
$26,000,000
$20.21 P/Share
|
|
Nov 17
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
539,650
-1.58%
|
$10,793,000
$20.51 P/Share
|
|
Nov 14
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,027,670
-2.92%
|
$20,553,400
$20.33 P/Share
|
|
Nov 13
2025
|
Vivek Ramaswamy > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
287,283
-0.81%
|
$5,745,660
$20.81 P/Share
|
|
Nov 07
2025
|
Eric Venker President & Immunovant CEO |
SELL
Open market or private sale
|
Direct |
200,000
-11.73%
|
$4,000,000
$20.22 P/Share
|
|
Nov 07
2025
|
Eric Venker President & Immunovant CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
200,000
+10.5%
|
$600,000
$3.85 P/Share
|
|
Oct 20
2025
|
Ilan Oren |
SELL
Payment of exercise price or tax liability
|
Direct |
281
-0.24%
|
$4,777
$17.74 P/Share
|